Merck & Co Inc's MRK.N Japan unit and partner Ono Pharmaceutical Co Ltd have filed with regulators for approval to sell Merck's diabetes treatment Januvia in Japan
Merck & Co Inc's MRK.N Japan unit and partner Ono Pharmaceutical Co Ltd have filed with regulators for approval to sell Merck's diabetes treatment Januvia in Japan. Januvia was approved for use by itself, with the widely used drug metformin, or with members of another class of diabetes drugs called thiazolidinediones, such as Takeda Pharmaceutical's 4502.T Actos
Merck had received reports that some patients taking Januvia developed serious complications, including a potentially fatal skin condition called Stevens-Johnson Syndrome and serious allergic reactions. But it said no causal link between the drug and the conditions has been established.
